LONDON, October 17 /PRNewswire/ -- The current issue of Expert Opinion
on Investigational Drugs features the first in a series of reports by key
opinion leaders analysing discontinued drugs in 2005.
Dr Keith Suckling (formerly GlaxoSmithKline, UK) provides his expert
opinion on cardiovascular drugs that were dropped from clinical development
in 2005; and Professor Lloyd Kelland (Head of Biology, Wolfson Institute
for Biomedical Research, University College London) discusses the 20 drugs
discontinued in 2005 in the field of oncology.
These will be followed in later issues by papers on pulmonary,
dermatological, gastrointestinal and arthritis drugs by Professor Kenneth
KC Lee (The Chinese University of Hong Kong); drugs for disorders of the
central nervous system by Professor Robert Kerwin (Professor of Clinical
Neuropharmacology, Institute of Psychiatry, King's College London);
anti-infectives by Dr Nafsika Georgopapadakou (MethylGene); and renal,
endocrine and metabolic drugs by Dr Jerry Colca (Kalamazoo Metabolic
Research).
The series of papers is introduced by an editorial, featured in the
November issue, by Dr Louis A Tartaglia (Senior Vice President and General
Manager, Drug Repositioning and Selection, Gene Logic) on the value of drug
repositioning.
Data from the Pharmaprojects drug R&D pipeline database estimates
around 100 compounds are discontinued every year, at an enormous cost to
the pharmaceutical industry. There is clearly a need to identify the
reasons for these failures and develop better and more efficient methods to
avoid such losses in future.
TARTAGLIA LA: Complementary new approaches enable repositioning of
failed drug candidates. Expert Opin. Investig. Drugs (2006)
15(11):1295-1298 doi:10.1517/13543784.15.11.1295
http://www.expertopin.com/doi/abs/10.1517/13543784.15.11.1295
SUCKLING K: Discontinued drugs in 2005: cardiovascular drugs. Expert
Opin. Investig. Drugs (2006) 15(11):1299-1308
doi:10.1517/13543784.15.11.1299
http://www.expertopin.com/doi/abs/10.1517/13543784.15.11.1299
KELLAND L: Discontinued drugs in 2005: oncology drugs. Expert Opin.
Investig. Drugs (2006) 15(11):1309-1318 doi:10.1517/13543784.15.11.1309
http://www.expertopin.com/doi/abs/10.1517/13543784.15.11.1309
About Expert Opinion
For over a decade, the Expert Opinion series has provided systematic
and authoritative reviews to support every stage of the drug discovery and
R&D pipeline from target to market. Each of the ten journals in the series
covers a specific aspect of the pharmaceutical pipeline.
The series contains the following journals: Expert Opinion on
Biological Therapy, Expert Opinion on Drug Delivery, Expert Opinion on Drug
Metabolism & Toxicology, Expert Opinion on Drug Safety, Expert Opinion on
Emerging Drugs, Expert Opinion on Investigational Drugs, Expert Opinion on
Pharmacotherapy, Expert Opinion on Therapeutic Patents, Expert Opinion on
Therapeutic Targets and Expert Opinion on Drug Discovery.
For further information:
Phil Garner, Publisher
Telephone: +44-(0)20-7017-6775
Email: phil.garner@informa.com
Website: http://www.expertopin.com
SOURCE Expert Opinion
 back to top
CONTACT:
For further information: Phil Garner,
Publisher, Telephone: +44-(0)20-7017-6775, Email:
phil.garner@informa.com, Website: http://www.expertopin.com
|
